[JLABS Family] LiveStorm

Add this event to your calendar:
25/01/2018 11:00 25/01/2018 14:00 America/Toronto [JLABS Family] LiveStorm JLABS @ Toronto , 661 University Ave , Toronto , ON M5G 1M1 JLABS @ Toronto false DD/MM/YYYY

[JLABS Family] LiveStorm

JLABS @ Toronto , 661 University Ave , Toronto , ON M5G 1M1

January 25, 2018 from 11:00 AM to 14:00 PM (EST)

$10 - $35

Come one, come all! You are invited to learn more about some of the exciting companies creating scientific breakthroughs at JLABS in Toronto. JLABS @ Toronto officially has been open for a year and a half and currently has 45+ companies with several more in the pipeline. Five companies will give candid, informative presentations detailing their executive teams, an overview of their company and highlighting their reasons for joining JLABS. Don't miss this opportunity to learn more about the progress of this exciting project and meet the companies within JLABS. Please note that the presentations at this event will include publicly available, non-confidential information only.

Thursday January 25th, 2017

10:00AM | Registration
10:30AM | Presentations
11:45PM | Q&A
12:00PM | Lunch & Networking
1:00pm | Program Close
* Light food and beverage provided

Presenting Companies:
Acorn Biolabs Inc. read more»
Cyclica Inc. read more»
Mediphage Bioceuticals read more»
Qing Bile Therapeutics Inc. read more»
SYNG Pharma read more»

Please RSVP online so that we can get an accurate headcount for food and beverages. We will not be accepting walk-ups once the event is sold out.

JLABS @ Toronto
661 University Ave, Suite 1300
Toronto, ON M5G 0B7

Presenting Companies' Descriptions:
Acorn Biolabs Inc.
People’s own cells and genomes are becoming the foundation of current and future biomedical therapeutics. Aged cells, however, are highly mutated, deteriorated versions of our current cells. Acorn Biolabs has developed a mail-in non-invasive cell collection kit to cryopreserve and sequence people’s cells, empowering them with information today and preparing them for future therapeutics.
Web: acornbiolabs.com

Cyclica Inc.
Cyclica’s cloud-based Software-as-a-Service platform, Ligand Express™ combines an innovative structure-based proteome-wide screening technology with artificial intelligence to help scientists discover better medicines by uncovering and explaining the polypharmacological effects of small molecule therapeutics.
Web: cyclicarx.com

Mediphage Bioceuticals
Mediphage Bioceuticals (MB) is a University of Waterloo spin-off biotechnology company that focuses on the manipulation of bacteriophages and prokaryotic genetics to develop new therapeutic platforms that confer safe, effective and scalable treatment solutions for human disease.
Web: mediphage.ca

Qing Bile Therapeutics Inc.
Qing Bile Therapeutics Inc. is created in 2015 to develop and commercialize effective pharmaceuticals based on its unique proprietary Tetrahydroxylated Bile Acid (THBA) Platform to treat bile acid imbalance metabolic diseases. There is tremendous untapped potential to intervene, to produce therapeutics for a host of unmet medical needs.

SYNG Pharma
A peptide-drug company developing first-in-class therapies and diagnostics for endometriosis and prostate cancer.
Web: syngpharma.com

JLABS @ Toronto

About Johnson & Johnson Innovation, JLABS Johnson & Johnson Innovation, JLABS (JLABS) is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-saving, life-enhancing health and wellness solutions to patients around the world. JLABS achieves this by providing the optimal environment for emerging companies to catalyze growth and optimize their research and development by opening them to vital industry connections, delivering entrepreneurial programs and providing a capital-efficient, flexible platform where they can transform the scientific discoveries of today into the breakthrough healthcare solutions of tomorrow. At JLABS we value great ideas and are passionate about removing obstacles to success to help innovators unleash the potential of their early scientific discoveries. JLABS is a no-strings-attached model, which means entrepreneurs are free to develop their science while holding on to their intellectual property. JLABS is open to entrepreneurs across a broad healthcare spectrum including pharmaceutical, medical device, consumer and healthtech sectors. The JLABS flagship opened in 2012 in San Diego at Janssen's West Coast Research Center, and since then has grown to ten global locations including the Bay Area, Boston & Lowell, MA, Houston, Toronto, Beerse (Belgium), with New York City, opening in June 2018, and Shanghai in 2019. For more information please visit www.jlabs.jnjinnovation.com or follow @JLABS. About Johnson & Johnson Innovation Johnson & Johnson Innovation focuses on accelerating all stages of innovation worldwide and forming collaborations between entrepreneurs and Johnson & Johnson's global healthcare businesses. Johnson & Johnson Innovation provides scientists, entrepreneurs and emerging companies with one-stop access to science and technology experts who can facilitate collaborations across the pharmaceutical, medical device and consumer companies of Johnson & Johnson. Under the Johnson & Johnson Innovation umbrella of businesses, we connect with innovators through our regional Innovation Centers, Johnson & Johnson Innovation | JLABS, Johnson & Johnson Innovation - JJDC, and our Business Development teams to create customized deals and novel collaborations that speed development of innovations to solve unmet needs in patients. For more information please visit www.jnjinnovation.com or follow @JNJInnovation.

Event contact

Related content